Can ibrutinib be used as a first-line treatment in CLL?
Checkpoint inhibitors in Hodgkin lymphoma
The important issues to consider when deciding when a multiple myeloma patient must start treatment
Clinicogenetic risk models to predict outcome of follicular lymphoma patients
Individualising treatment for elderly MM patients